Quarterly report pursuant to Section 13 or 15(d)

Revenue - Potential Milestone Payments (Details)

v3.20.1
Revenue - Potential Milestone Payments (Details) - Strategic Partnerships and Other License Agreements
$ in Millions
Mar. 31, 2020
USD ($)
Research, Development, Regulatory & Commercial Milestones  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments $ 2,547
Research, Development, Regulatory & Commercial Milestones | AstraZeneca  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 1,111
Research, Development, Regulatory & Commercial Milestones | Servier  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 667
Research, Development, Regulatory & Commercial Milestones | Seattle Genetics  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 769
Sales Milestones  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 2,002
Sales Milestones | AstraZeneca  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 960
Sales Milestones | Servier  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments 592
Sales Milestones | Seattle Genetics  
Revenue Recognition, Milestone Method [Line Items]  
Total potential milestone payments $ 450